Comparison of systemic inflammatory profiles in COVID-19 and community-acquired pneumonia patients: a prospective cohort study.
COVID-19
Community-acquired pneumonia
Cytokines
Immunology
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
22 Feb 2023
22 Feb 2023
Historique:
received:
11
04
2022
accepted:
28
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Inflammatory responses contribute to tissue damage in COVID-19 and community-acquired pneumonia (CAP). Although predictive values of different inflammatory biomarkers have been reported in both, similarities and differences of inflammatory profiles between these conditions remain uncertain. Therefore, we aimed to determine the similarities and differences of the inflammatory profiles between COVID-19 and CAP, and their association with clinical outcomes. We report a prospective observational cohort study; conducted in a reference hospital in Latin America. Patients with confirmed COVID-19 pneumonia and CAP were included. Multiplex (Luminex) cytokine assays were used to measure the plasma concentration of 14 cytokines at hospital admission. After comparing similarities and differences in the inflammatory profile between COVID-19 and CAP patients, an unsupervised classification method (i.e., hierarchical clustering) was used to identify subpopulations within COVID-19 and CAP patients. A total of 160 patients were included, 62.5% were diagnosed with COVID-19 (100/160), and 37.5% with CAP (60/160). Using the hierarchical clustering, COVID-19 and CAP patients were divided based on its inflammatory profile: pauci, moderate, and hyper-inflammatory immune response. COVID-19 hyper-inflammatory subpopulation had the highest mortality. COVID-19 hyper-inflammatory subpopulation, compared to pauci-inflammatory, had higher levels of IL-10 (median [IQR] 61.4 [42.0-109.4] vs 13.0 [5.0-24.9], P: < 0.001), IL-6 (48.1 [22.3-82.6] vs 9.1 [0.1-30.4], P: < 0.001), among others. Hyper-inflammatory vs pauci-inflammatory CAP patients were characterized by elevation of IFN2 (48.8 [29.7-110.5] vs 3.0 [1.7-10.3], P: < 0.001), TNFα (36.3 [24.8-53.4] vs 13.1 [11.3-16.9], P: < 0.001), among others. Hyper-inflammatory subpopulations in COVID-19 and CAP compared to the corresponding pauci-inflammatory subpopulations had higher MCP-1. Our data highlights three distinct subpopulations in COVID-19 and CAP, with differences in inflammatory marker profiles and risks of adverse clinical outcomes. This is a prospective study, therefore no health care intervention were applied to participants and trial registration is not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory responses contribute to tissue damage in COVID-19 and community-acquired pneumonia (CAP). Although predictive values of different inflammatory biomarkers have been reported in both, similarities and differences of inflammatory profiles between these conditions remain uncertain. Therefore, we aimed to determine the similarities and differences of the inflammatory profiles between COVID-19 and CAP, and their association with clinical outcomes.
METHODS
METHODS
We report a prospective observational cohort study; conducted in a reference hospital in Latin America. Patients with confirmed COVID-19 pneumonia and CAP were included. Multiplex (Luminex) cytokine assays were used to measure the plasma concentration of 14 cytokines at hospital admission. After comparing similarities and differences in the inflammatory profile between COVID-19 and CAP patients, an unsupervised classification method (i.e., hierarchical clustering) was used to identify subpopulations within COVID-19 and CAP patients.
RESULTS
RESULTS
A total of 160 patients were included, 62.5% were diagnosed with COVID-19 (100/160), and 37.5% with CAP (60/160). Using the hierarchical clustering, COVID-19 and CAP patients were divided based on its inflammatory profile: pauci, moderate, and hyper-inflammatory immune response. COVID-19 hyper-inflammatory subpopulation had the highest mortality. COVID-19 hyper-inflammatory subpopulation, compared to pauci-inflammatory, had higher levels of IL-10 (median [IQR] 61.4 [42.0-109.4] vs 13.0 [5.0-24.9], P: < 0.001), IL-6 (48.1 [22.3-82.6] vs 9.1 [0.1-30.4], P: < 0.001), among others. Hyper-inflammatory vs pauci-inflammatory CAP patients were characterized by elevation of IFN2 (48.8 [29.7-110.5] vs 3.0 [1.7-10.3], P: < 0.001), TNFα (36.3 [24.8-53.4] vs 13.1 [11.3-16.9], P: < 0.001), among others. Hyper-inflammatory subpopulations in COVID-19 and CAP compared to the corresponding pauci-inflammatory subpopulations had higher MCP-1.
CONCLUSIONS
CONCLUSIONS
Our data highlights three distinct subpopulations in COVID-19 and CAP, with differences in inflammatory marker profiles and risks of adverse clinical outcomes.
TRIAL REGISTRATION
BACKGROUND
This is a prospective study, therefore no health care intervention were applied to participants and trial registration is not applicable.
Identifiants
pubmed: 36814234
doi: 10.1186/s12931-023-02352-2
pii: 10.1186/s12931-023-02352-2
pmc: PMC9944840
doi:
Substances chimiques
Cytokines
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
JAMA. 2015 Feb 17;313(7):677-86
pubmed: 25688779
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
J Crit Care. 2022 Jun;69:154014
pubmed: 35217370
Curr Infect Dis Rep. 2016 Mar;18(3):10
pubmed: 26874956
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Clin Microbiol Rev. 2021 Jan 13;34(2):
pubmed: 33441314
Front Immunol. 2020 Dec 14;11:614801
pubmed: 33424869
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Intensive Care Med. 2018 Sep;44(9):1470-1482
pubmed: 30074052
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Am J Physiol Lung Cell Mol Physiol. 2020 Feb 1;318(2):L215-L225
pubmed: 31774305
Crit Care. 2021 Feb 15;25(1):63
pubmed: 33588914
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Clinics (Sao Paulo). 2021 Jul 05;76:e2900
pubmed: 34231709
Cytokine. 2021 Jul;143:155523
pubmed: 33840589
Ann Intensive Care. 2021 Nov 26;11(1):159
pubmed: 34825976
Ann Am Thorac Soc. 2020 Jul;17(7):879-891
pubmed: 32267771
Ann Palliat Med. 2021 Apr;10(4):3706-3714
pubmed: 33615814
Am J Respir Crit Care Med. 2020 Sep 15;202(6):784-786
pubmed: 32755507
Curr Opin Crit Care. 2019 Oct;25(5):489-497
pubmed: 31335383
Curr Opin Infect Dis. 2021 Apr 1;34(2):135-141
pubmed: 33470665
Nature. 2021 Feb;590(7847):635-641
pubmed: 33429418
Lancet Respir Med. 2020 Dec;8(12):1233-1244
pubmed: 33075298
Lancet. 2021 Sep 4;398(10303):906-919
pubmed: 34481570
Arch Intern Med. 2007 Aug 13-27;167(15):1655-63
pubmed: 17698689
ERJ Open Res. 2022 Feb 14;8(1):
pubmed: 35169585
Med Clin North Am. 2019 May;103(3):487-501
pubmed: 30955516
Front Immunol. 2022 Jan 11;12:815651
pubmed: 35087533
Infection. 2021 Aug;49(4):607-616
pubmed: 33782861
Am J Respir Crit Care Med. 2020 Sep 15;202(6):812-821
pubmed: 32584597
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413139
Int Immunopharmacol. 2021 Aug;97:107685
pubmed: 33951560
Crit Care Clin. 2013 Jul;29(3):563-601
pubmed: 23830654